Re-analysis of the AEGIS H2H study showed that Ferracru/Accrufer is a credible alternative to IV therapy for iron deficiency anaemia and that it corrects anaemia and maintains haemoglobin (Hb) levels over the long term. Although Feraccru did not technically achieve non-inferiority versus IV iron at 12 weeks, the long-term benefits and health economic arguments for using Feraccru remain as strong as ever. The regulatory status of Feraccru is unaffected by this result and is unlikely, in our vi
07 Aug 2020
Shield Therapeutics - Re-analysis of H2H data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Re-analysis of H2H data
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
07 Aug 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
5
Re-analysis of the AEGIS H2H study showed that Ferracru/Accrufer is a credible alternative to IV therapy for iron deficiency anaemia and that it corrects anaemia and maintains haemoglobin (Hb) levels over the long term. Although Feraccru did not technically achieve non-inferiority versus IV iron at 12 weeks, the long-term benefits and health economic arguments for using Feraccru remain as strong as ever. The regulatory status of Feraccru is unaffected by this result and is unlikely, in our vi